Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension

03 October 2020: Clinical Research

Zirui Hao ^1BCDE , Yue Sun ^1BF , Yingzhen Wen ^1BF , Lijuan Cui ^1BF , Guiping Li ^1DF , Yan Liu ^2AG*

DOI: 10.12659/MSM.925987

Med Sci Monit 2020; 26:e925987

Table 4 Relationship between 24-h ABP and dapagliflozin treatment.

	β	R2	P
24-h SBP
Unadjusted	−0.58	0.37
Adjusted model 1	−0.29	0.25	0.02
Adjusted model 2	−0.12	0.14	0.10
24-h DBP
Unadjusted	−0.14	0.10	0.18
Adjusted model 1	−0.06	0.05	0.34
Adjusted model 2	−0.02	0.02	0.63
Daytime SBP
Unadjusted	−0.62	0.41
Adjusted model 1	−0.33	0.32	0.009
Adjusted model 2	−0.20	0.19	0.06
Daytime DBP
Unadjusted	−0.16	0.11	0.12
Adjusted model 1	−0.09	0.05	0.23
Adjusted model 2	−0.03	0.02	0.40
Nighttime SBP
Unadjusted	−0.30	0.26	0.04
Adjusted model 1	−0.11	0.12	0.09
Adjusted model 2	−0.07	0.08	0.21
Nighttime DBP
Unadjusted	−0.10	0.14	0.32
Adjusted model 1	−0.07	0.06	0.48
Adjusted model 2	−0.03	0.02	0.63
SBP – systolic blood pressure; DBP – diastolic blood pressure. Model 1: adjusted for age, female sex, body mass index, estimated glomerular filtration rate, medication use at follow-up (aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, calcium channel blocker, beta-blocker, and metformin); and glycated hemoglobin A1c, urine albumin-creatinine ratio and 24-h urine volume at follow-up. Model 2: was additionally adjusted for serum uric acid and 24-h urinary uric acid excretion at follow-up.